← Amneal Pharmaceuticals, Inc. AMRX
Market Price
$18.16
Market Cap
$5.51B
P/E Ratio
N/A
Revenue (FY 2025)
↑8.0% YoY
$3.02B
3-Yr CAGR: 10.9%
Net Income
↑273.2% YoY
$127.93M
Net Margin: 4.2%
Free Cash Flow
↑8.6% YoY
$311.21M
FCF Yield: 5.65%
EPS (Diluted)
N/A
Basic: N/A
Return on Equity
Efficiency
N/A
ROA: 3.5%
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (AMRX)
All monetary values in millions ($M)| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2017 | $1,033.7M | — | $526.2M | $169.3M | — | — | — | $234.2M | $234.2M | — |
| FY 2018 | $1,663.0M | +60.9% | $716.4M | $-201.3M | -218.9% | — | — | $250.2M | $250.2M | +6.9% |
| FY 2019 | $1,626.4M | -2.2% | $353.0M | $-603.6M | -199.8% | — | — | $1.7M | $1.7M | -99.3% |
| FY 2020 | $1,992.5M | +22.5% | $628.4M | $68.6M | +111.4% | — | — | $379.0M | $373.6M | +21,812.6% |
| FY 2021 | $2,093.7M | +5.1% | $769.0M | $20.2M | -70.6% | — | — | $241.8M | $238.6M | -36.1% |
| FY 2022 | $2,212.3M | +5.7% | $784.7M | $-254.8M | -1,363.2% | — | — | $65.1M | $62.7M | -73.7% |
| FY 2023 | $2,393.6M | +8.2% | $820.6M | $-48.7M | +80.9% | — | — | $345.6M | $342.0M | +445.3% |
| FY 2024 | $2,794.0M | +16.7% | $1,020.4M | $-73.9M | -51.6% | — | — | $295.1M | $286.7M | -16.2% |
| FY 2025 | $3,018.8M | +8.0% | $1,113.3M | $127.9M | +273.2% | — | — | $340.0M | $311.2M | +8.6% |
Valuation
Market Price
$18.16
Market Cap
$5.51B
Enterprise Value
$7.79B
P/E Ratio
N/A
P/B Ratio
N/A
FCF Yield
5.65%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
36.88%
Operating Margin
13.05%
Net Margin
4.24%
Return on Equity (ROE)
N/A
Return on Assets (ROA)
3.48%
Asset Turnover
0.82x
Revenue 3-Yr CAGR
10.92%
Financial Health & Liquidity
Current Ratio
0.11
Cash Ratio
0.32
Debt / Equity
N/A
Debt / Assets
0.697
Cash & Equivalents
$282.03M
Total Debt
$2.57B
Book Value / Share
N/A
Cash Flow Efficiency
Operating Cash Flow
$339.99M
Capital Expenditures (CapEx)
$28.78M
Free Cash Flow
$311.21M
OCF / Revenue
11.26%
FCF / Revenue
10.31%
FCF 3-Yr CAGR
70.57%
Per Share Metrics
EPS (Diluted)
N/A
EPS (Basic)
N/A
Dividends / Share
N/A
Book Value / Share
N/A
EPS YoY Growth
N/A
Balance Sheet (FY 2025)
Total Assets
$3.68B
Total Liabilities
$3.68B
Stockholders' Equity
N/A
Current Assets
$98.39M
Current Liabilities
$881.63M